Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 UPM, Amerigen Enter Long-Term Mfg. Pact | Contract Pharma
Breaking News

UPM, Amerigen Enter Long-Term Mfg. Pact

Will supply two products under 10-year supply pact

UPM, a division of Gregory Pharmaceutical Holdings, Inc., has entered an agreement with Amerigen Pharmaceuticals, Inc. to manufacture two ANDA products for a 10- year commercial supply term. Also, UPM may potentially develop and supply several additional ANDA products for Amerigen under the agreement.  

Back in July 2013, UPM acquired Pfizer’s 475,000 sq.-ft. manufacturing facility in Bristol, TN, which is where all of these products will eventually be made.  

Dr. John M. Gregory, chairman and chief executive officer of Gregory Pharmaceutical Holdings, Inc., said, “UPM has been working with Amerigen for the past three years. We have a strong working relationship with their company and are impressed with their technical team and their business development approach. We believe this agreement cements our partnership with Amerigen. Also, it is another example of UPM’s transition from a company that formerly focused on only early stage development, but now, provides a full range of solid dose commercial services for our clients.”  

Jonathan Embleton, chief business officer of Amerigen, said, “Amerigen looks forward to a long relationship with UPM.  We are excited about our upcoming product portfolio and the role UPM will play in providing products to market.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters